GentiBio
Emily is the Associate Director of Accounting Operations. She is originally from Connecticut and earned her BS in Accounting from the University of Connecticut. Prior to Gentibio, Emily worked on the accounting teams at Blueprint Medicines and Editas Medicine where she helped develop streamlined month-close processes and various Sarbanes Oxley compliant procedures. Her career began as an auditor with the accounting firm KPMG.
GentiBio
GentiBio, Inc., is an early stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complimentary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or malfunctioning of the immune system.